Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
May 21, 2024 16:15 ET
|
Aerovate Therapeutics, Inc.
Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of...
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
May 13, 2024 16:30 ET
|
Aerovate Therapeutics, Inc.
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Enrollment continues into the Phase 3...
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
March 27, 2024 09:20 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of...
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
March 25, 2024 16:10 ET
|
Aerovate Therapeutics, Inc.
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Completed enrollment in the Phase 2b...
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
March 06, 2024 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of...
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
November 20, 2023 16:45 ET
|
Aerovate Therapeutics, Inc.
Topline Phase 2b data expected in June 2024 More than 120 sites around the world actively recruiting in the Phase 3 portion of the IMPAHCT trial WALTHAM, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) --...
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
November 13, 2023 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
August 14, 2023 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
July 11, 2023 17:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
June 01, 2023 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the...